Share ownership Evaxion A/S

EVAX

US29970R3030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 14/03/2026 +04			5-day change	1st Jan Change
4.260 ^USD	+1.91%		+32.30%	-10.69%

03-13	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
03-12	European Equities Traded in US as ADRs Slump in Thursday Trading	MT

Share class: Evaxion A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	54,110,546	40,447,633 ( 74.75 %)	0	74.75 %

Major shareholders: Evaxion A/S

Name	Equities	%	Valuation
MERCK & CO., INC. 19.22 %	1,214,126	19.22 %	4 M $
Ikarian Capital LLC 1.183 %	74,698	1.183 %	236 046 $
PSM Vermögensverwaltung GmbH Langen v.d.Goltz, Dr. Prinz 0.6333 %	40,000	0.6333 %	126 400 $
Point72 Asset Management LP 0.524 %	33,100	0.524 %	104 596 $
RhumbLine Advisers LP 0.3339 %	21,090	0.3339 %	66 644 $
Stonepine Capital Management LLC 0.3166 %	20,000	0.3166 %	63 200 $
Boothbay Fund Management LLC 0.2917 %	18,426	0.2917 %	58 226 $
SmartHarvest Portfolios LLC 0.2405 %	15,194	0.2405 %	48 013 $
WesBanco Bank, Inc. (Investment Management) 0.1583 %	10,000	0.1583 %	31 600 $
Northwestern Mutual Wealth Management Co. 0.1267 %	8,000	0.1267 %	25 280 $
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
MERCK & CO., INC. 19.22 %	60,706,348	19.22 %	19 M $
Andreas Mattsson 1.749 %	5,524,966	1.749 %	2 M $
Marianne Søgaard 1.223 %	3,863,115	1.223 %	1 M $
Roberto Prego Pineda 0.3708 %	1,171,030	0.3708 %	370 045 $
Thomas Schmidt 0.2045 %	646,020	0.2045 %	204 142 $
Lars Holtug 0.0722 %	228,029	0.0722 %	72 057 $
Lars Wegner 0.0409 %	129,139	0.0409 %	40 808 $
Birgitte Rono 0.0116 %	36,765	0.0116 %	11 618 $
Helena Tayton-Martin 0 %	0	0 %	- $

Breakdown by shareholder type

Merck & Co., Inc.	980.19%
Individuals	183.61%
Institutional	3.87%
Other	0.16%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	983.59%
Individuals	183.63%
Germany	0.63%
Canada	0.06%
Switzerland	0.03%

Based on 1000 largest holdings

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Employees

Sector

Biotechnology & Medical Research

Calendar

05-07 - Earnings release - Q1 2026

More about the company